He told the Minister of Science that the United Kingdom is “determined to solve” its confrontation with the pharmaceutical industry and reflected a 10 -year decrease in NHS on medicines.
Patrick Vallas, a former executive of the GSK, said the country needs to increase spending on medicines and reflect a decade of low investment.
“We are determined to solve this,” said Lord Vallafa to the General Science Committee. “This is not something [where] We are sitting, let’s watch the decline in industry. This is what happened over the past ten years. We should not do that. We have to act. Now a pivotal moment … to try to get this correctly. “
Representatives invited the emergency session in response to the decision last week from the American pharmaceutical maker Merck, known as MSD in Europe, to cancel his plans for the London Research Center worth 1 billion pounds and put 125 parties partially headquarters at the Francis Kreik Institute in the capital. MSD blames “UK challenges do not make a male progress towards addressing the lack of investment in the life science industry.”
On Friday, Astrazneca announced that it had set a new laboratory worth 200 million pounds in Cambridge, after giving up an investment of 450 million pounds at its vaccine site in Spok in the next January of negotiations, citing a reduction in government support.
Valsa, who became a familiar name as the chief scientific advisor during the Koronverus virus, told MPS on Tuesday that NHS on medicines was decreased as a percentage of the total health care spending since 2015, but he said that the number would increase from the current 9 %.
He added: “The reason is that we need the opposite of this trend is not just the price … It is related to saying that we need to make sure that we are getting a rapid absorption of the best new drugs and we have fair arrival throughout the United Kingdom.”
The Minister of Science said that the drug regulator, the organizational agency for medicines, health care products and the National Institute for Excellence in the field of health and care, which decide the medicines available on NHS, which must be linked.
Dr. Zubair Ahmed, the new Undersecretary of the State of the State of the State and the Scottish surgeon, said that the United Kingdom needs to change its pricing models in appreciation of the new advanced treatments, which are more expensive.
He added: “We have to look at medicines in a different light … and calculate the economic and secrecy benefit on this basis.”
Although although the government did not re -operate talks with the pharmaceutical industry on the pharmaceutical mechanism, which collapsed last month without agreement and was martyred as one of the factors in the drug makers who canceled the projects, the ministers were dragging “many discussions on the commercial environment in the United Kingdom.”
After promoting the newsletter
“We cannot lose this industry from the United Kingdom,” he said. He added: “It is extremely important to have two large global companies. This matters, they are two,” referring to Astrazeneca and GSK.
Earlier on Tuesday, the deputies of the UK president, Bin Lucas, who said it was “a sad day we leave because we appreciate our cooperation with the Crik.” The company also plans to close the animal health site in Milton Keynes and move the work to Austria.
“We are now involved in a very constructive conversation with the government at the highest level, although this is a very difficult moment in history and a very big challenge,” MPS told MPS.
Richard Torbit, President of the British Pharmaceutical Society, warned that the United Kingdom is losing to the United States, Belgium, Ireland, Singapore and Germany.